In:
Blood, American Society of Hematology, Vol. 124, No. 23 ( 2014-11-27), p. 3398-3408
Kurzfassung:
A currently marketed rFVIII product is associated with a higher risk of inhibitor development in boys with severe hemophilia A. This result, validated by extensive sensitivity analyses, confirms a recently published study and cannot be explained by identified biases.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2014-07-586347
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2014
ZDB Id:
1468538-3
ZDB Id:
80069-7